Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2159034 | 0.88 | MAPT (0.42) | MYCMAPTHDAC8ALDH1A1GAA | |
| SCHEMBL4242290 | 0.84 | MAPK1 (0.48) | MYCMAPK1CYP3A4CYP2C9ALOX12 | |
| SCHEMBL1965798 | 0.82 | CA12 (0.37) | MYCMAPTHDAC8ALDH1A1LMNA | |
| SCHEMBL4237016 | 0.80 | MYC (0.41) | MYCMAPK1CYP3A4CYP2C9ALOX12 | |
| SCHEMBL27593234 | 0.78 | ACE2 (0.40) | CYP2C9ALOX12MAPTHDAC8GAA | |
| SCHEMBL2207409 | 0.78 | ALDH1A1 (0.51) | MAPK1CYP3A4CYP2C9L3MBTL1MAPT | |
| SCHEMBL4239362 | 0.77 | PTPN11 (0.52) | MAPK1CYP3A4L3MBTL1ALDH1A1LMNA | |
| SCHEMBL27766677 | 0.77 | ALDH1A1 (0.46) | MYCMAPTALDH1A1GAALMNA | |
| SCHEMBL7203924 | 0.76 | AAK1 (0.39) | ALDH1A1LMNAHSD17B10AAK1 | |
| SCHEMBL29168896 | 0.76 | GABRA1 (0.41) | ALDH1A1LMNAAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106099-B2 | 2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide or other phenylcarboxamide derivatives with dofetilide, ibutilide, almokalant, sotalol, azimilide, amiodarone, E4031, clofilium, ambasilide, MS551, tedisamil, bertosamil and quinidine as IKr chahel blocker | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-7982045-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| EP-1605976-B1 | PHENYLCARBOXYL ACID AMIDES AND IK r CHANNEL INHIBITORS COMBINATION AND THE USE THEREOF FOR TREATING ATRIAL ARRHYTHMIA | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-02-24 | — | — | EP | disclosed |
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-30 | — | — | US | disclosed |
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7514582-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-07 | — | — | US | disclosed |
| EP-2012758-A2 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | Sanofi-Aventis Deutschland GmbH (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007124849-A2 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070043091-A1 | Kv1.5-BLOCKER FOR THE SELECTIVE INCREASE OF ATRIAL CONTRACTILITY AND TREATMENT OF CARDIAC INSUFFICIENCY | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-1720549-A1 | KV1.5-BLOCKER FOR THE SELECTIVE INCREASE OF ATRIAL CONTRACTILITY AND TREATMENT OF CARDIAC INSUFFICIENCY | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005025674-A1 | COMBINATION OF PHENYLCARBOXAMIDES WITH BETA-ADRENERGIC RECEPTOR BLOCKERS AND USE THEREOF FOR THE TREATMENT OF ATRIAL ARRHYTHMIAS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054673-A1 | Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20050038083-A1 | Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-17 | — | — | US | disclosed |
| WO-2004082716-A1 | PHENYLCARBOXYL ACID AMIDES AND IKr CHANNEL INHIBITORS COMBINATION AND THE USE THEREOF FOR TREATING ATRIAL ARRHYTHMIA | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | WO | disclosed |
| US-20040102513-A1 | 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-05-27 | — | — | US | disclosed |
| US-6686395-B2 | THERAPY OF A CARDIAC ARRYTHMIA WHICH CAN BE ELIMINATED BY ACTION POTENTIAL PROLONGATION; POTASSIUM CHANNEL MODULATOR | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-03 | — | — | US | disclosed |
| US-20030171351-A1 | 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-09-11 | — | — | US | disclosed |
| US-6531495-B1 | Potassium channel | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-11 | — | — | US | disclosed |
| EP-1222163-A1 | 2'-SUBSTITUTED 1,1'-BIPHENYL-2-CARBONAMIDES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001025189-A1 | 2'-SUBSTITUTED 1,1'-BIPHENYL-2-CARBONAMIDES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038083-A1 | Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias | KCNH2, KCNJ2, KCNH1 | MYC 1894/4885MAPK1 3122/4885CYP3A4 378/4885 |
| US-20030171351-A1 | 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | MLLT3, RYR2, KCNH1 | MYC 4593/4885MAPK1 2051/4885CYP3A4 38/4885 |
| US-20050054673-A1 | Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias | SCN5A, KCNH1, KCNA5 | MYC 3894/4885MAPK1 1611/4885CYP3A4 518/4885 |
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | KCNN3, CACNA1I, KCNN1 | MYC 1075/4885MAPK1 2226/4885CYP3A4 1874/4885 |
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | MLLT3, RYR2, CACNA1E | MYC 4583/4885MAPK1 2294/4885CYP3A4 32/4885 |
| US-20070043091-A1 | Kv1.5-BLOCKER FOR THE SELECTIVE INCREASE OF ATRIAL CONTRACTILITY AND TREATMENT OF CARDIAC INSUFFICIENCY | KCNJ2, KCNH2, KCNK5 | MYC 3221/4885MAPK1 2053/4885CYP3A4 1702/4885 |
| US-20040102513-A1 | 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | MLLT3, RYR2, CACNA1E | MYC 4577/4885MAPK1 2117/4885CYP3A4 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.